FibroBiologics Partners With Charles River To Revolutionize Fibroblast Cell Therapy For Chronic Diseases

FibroBiologics, Inc. has signed a master services agreement with Charles River Laboratories. The company is worldwide leading in drug discovery, development, testing and manufacturing sectors. According to the agreement, Charles River will support, develop, and manufacture FibroBiologics’ fibroblast-based product, CYWC628, for a diabetic foot ulcer (DFU) clinical trial set to start in 2025. 

FibroBiologics is a clinical-stage biotech company with over 160 patents issued and ongoing development. The firm focuses on using fibroblasts and fibroblast-driven materials to discover possible therapies to treat chronic diseases using immunomodulatory and regenerative capabilities of fibroblasts and fibroblast-derived materials. Indications that have been evaluated include wound healing, multiple sclerosis, cancer, degenerative disc disease, psoriasis and thymic involution reversal. 

Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River, stated, “Charles River’s work with FibroBiologics is part of a larger commitment to supporting next-generation regenerative medicine through the adoption of innovative therapies. We are excited to collaborate with FibroBiologics and support the development of a therapy that has the potential to transform patient care for those impacted by diabetic foot wounds.”

The successful technology transfer to Charles River for CGMP and positive feasibility studies paved the way for Charles River to serve as the contract development and manufacturing organization (CDMO) for the trial. Charles River offers an industry-leading “concept to cure” advanced therapies solution. Charles River’s expertise in cell and gene therapy manufacturing will support the production of CYWC628 for FibroBiologics' upcoming clinical trial.

 Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, said in a statement, “The formalization of our working relationship with Charles River is a pivotal step as we advance toward a significant wound care clinical trial in 2025 with CYWC628. Working with Charles River opens new possibilities for innovation with its global reach and scalability potential; also continued, “ By combining our unique therapeutic fibroblast-based spheroids approach with Charles River’s expertise and unparalleled support, we are positioned to accelerate progress in delivering this treatment to patients.”